Clinical Analysis of Paclitaxel combined with Three-dimensional Conformal Radiotherapy for Advanced Cervical Cancer
To explore the clinical efficacy and safety of paclitaxel combined with three-dimensional conformal radiotherapy in the treatment of advanced cervical cancer. 102 patients with advanced cervical cancer admitted from August 2012 to August 2013 were randomly divided into observation group and control group, 51 cases in each group. All patients received intracavitary radiotherapy and paclitaxel chemotherapy. In addition, the observation group received three-dimensional conformal radiotherapy and the control group received intensity-modulated radiotherapy. The efficacy and safety of the two groups were compared and analyzed. The total effective rate in the observation group was higher than that in the control group [47 (92.15) VS.36 (70.59)], and the difference was statistically significant (P < 0.05). There were 45 cases of leukopenia, 12 cases of urinary system injury, 31 cases of digestive system injury and 18 cases of thrombocytopenia in the observation group, 47 cases of leukopenia, 14 cases of urinary system injury, 20 cases of digestive system injury and 6 cases of thrombocytopenia in the control group. There were significant differences between the two groups in the side effects of digestive system injury and thrombocytopenia (P < 0.05). In terms of five-year survival rate, there was significant difference between the two groups (P=0.04). In the observation group, 31 cases survived, 20 cases died, 21 cases survived and 30 cases died in the control group. Paclitaxel combined with three-dimensional conformal radiotherapy has a good therapeutic effect on patients with advanced cervical cancer, and has a high clinical value, which is worthy of promotion and application.